GSK

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)

Stock · NYSE · Health Care

$50.82as of 8/28/2026

AI Market Commentary

AI-generated

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

August 30, 2026

GSK in Focus as FDA Greenlights Newborn HIV Drug Amid Vaccine Debate. GSK recently received approval from the U.S. Food and Drug Administration for a new drug designed to treat HIV infections in newborns, expanding the company's pediatric portfolio. The news comes during a broader public discussion around vaccine policy, with figures such as Dr. Oz publicly defending the safety of the MMR vaccine as measles cases draw renewed attention in the United States. These developments highlight GSK's involvement in both infectious disease treatment and the wider vaccine conversation. Investors continue to note the company's established position in the healthcare sector.

Active signals

Resistance level
$51.27
Industry
Biotechnology: Pharmaceutical Preparations

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
66,841

Fundamentals

1-day range
$49.96$50.88
Market cap
$104.31B
P/E (trailing)
15.53
P/E (forward)
10.19
EPS (trailing)
$1.18
Dividend yield
3.92%
Beta
1.25
Avg. volume
3.92M
Ex-dividend date
August 14, 2026
Dividend pay date
October 8, 2026
52-week range
$1,441$2,282
Next earnings: October 28, 2026 · EPS estimate $1.34confirmed

Forecasts

8 analyst ratings

Buy 44%
Hold 47%
Sell 9%
1-year price forecast
High
$70
+37.7%
Median
$56
+10.2%
Low
$50
-1.6%

GSK plc American Depositary Shares (Each representing two Ordinary Shares) Competitors

Chosen by industry and closest market cap.

  • GSK
    GSK plc American Depositary Shares (Each representing two Ordinary Shares)
    $50.82
    ▲ 1.09%
    Market cap $104.31BP/E 15.53
    $1,441$2,282
  • SNY
    Sanofi ADS
    $44.82
    ▼ 0.04%
    Market cap $104.75BP/E 16.24
    $71.25$91.15
  • VRTX
    Vertex Pharmaceuticals Incorporated Common Stock
    $541.72
    ▼ 1.06%
    Market cap $119.47BP/E 30.70
    $374.17$555.69
  • PFE
    Pfizer Inc. Common Stock
    $27.95
    ▼ 0.25%
    Market cap $142.66BP/E 35.19
    $23.58$28.75
  • ONC
    BeOne Medicines Ltd. American Depositary Shares
    $366.79
    ▼ 1.53%
    Market cap $34.88BP/E 88.12
    $205.51$346
  • ZTS
    Zoetis Inc. Class A Common Stock
    $77.36
    ▲ 3.12%
    Market cap $32.32BP/E 11.54
    $71$156.49
  • ROIV
    Roivant Sciences Ltd. Common Shares
    $34.71
    ▼ 7.64%
    Market cap $24.08BP/E
    $11.85$37.97

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
378.40M
Total value held
$19.13B
Institutional holders
1024
Top holders this quarter
  • Unknown67.66M
  • Unknown58.66M
  • Unknown34.52M
  • Unknown25.20M
  • Unknown11.80M
  • Unknown11.72M
  • Unknown11.03M
  • Unknown10.29M
  • Unknown9.04M
  • Unknown7.51M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.